Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in glenmark

Glenmark Says Interim Data From Study Supports Favipiravir's Safety, Effectiveness

Glenmark received restricted emergency use approval from India's drug regulator for FabiFlu for the treatment of mild to moderate COVID-19.

Read More

Glenmark Q4 Net Profit Up 6 % At Rs 233.87 Cr

The company's revenue from operations stood at Rs 10,943.9 crore for the fiscal ended March 2021. It was Rs 10,641 crore in 2019-20

Read More

Glenmark Pharma Gets USFDA Nod For Icatibant Injection

The drug firm said its current portfolio consists of 172 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications are pending approval with the USFDA.

Read More

Glenmark Pharma To Launch Its Nasal Spray Ryaltris In EU

Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age.

Read More

Glenmark receives one ANDA approval and two tentative ANDA approvals - Tadalafil Gabapentin Enacarbil and Apremilast

Glenmark receives one ANDA approval and two tentative ANDA approvals - Tadalafil Gabapentin Enacarbil and Apremilast

Read More

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Read More

Glenmark Pharmaceuticals and Menarini enter into exclusive licensing agreement for commercializing Ryaltris™ nasal spray across numerous markets throughout Europe

Glenmark Pharmaceuticals and Menarini enter into exclusive licensing agreement for commercializing Ryaltris™ nasal spray across numerous markets throughout Europe

Read More

Glenmark Pharma Gets Tentative Nod From USFDA For Anticoagulant Drug

Quoting IQVIA sales data for the 12 month period ending August 2020, Glenmark said Pradaxa capsules, 75, 110 mg and 150 mg, market achieved annual sales of approximately USD 550.9 million.

Read More

Glenmark to divest select Anti-Allergy brands to Dr Reddy's in Russia, Ukraine, Kazakhstan and Uzbekistan in anticipation of its "Ryaltris" Launch

Glenmark to divest select Anti-Allergy brands to Dr Reddy's in Russia, Ukraine, Kazakhstan and Uzbekistan in anticipation of its "Ryaltris" Launch

Read More

Glenmark Pharma Gets USFDA Nod For Generic Drug

The company's US-based subsidiary has received final approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of PF Prism CV's Rapamune tablets

Read More

Glenmark's consolidated revenue grew by 0.94 per cent at Rs 23,447.87 million for Q1 FY 2020-21

Glenmark's consolidated revenue grew by 0.94 per cent at Rs 23,447.87 million for Q1 FY 2020-21

Read More

Glenmark introduces higher strength (400 mg) of FabiFlu® to reduce the pill burden of COVID-19 treatment

Glenmark introduces higher strength (400 mg) of FabiFlu® to reduce the pill burden of COVID-19 treatment

Read More

Glenmark announces top-line results from phase 3 clinical trial of Favipiravir in patients with mild to moderate COVID-19

Glenmark announces top-line results from phase 3 clinical trial of Favipiravir in patients with mild to moderate COVID-19

Read More

COVID-19: Glenmark's Favipiravir drug shows encouraging results in Phase 3 clinical trial

COVID-19: Glenmark's Favipiravir drug shows encouraging results in Phase 3 clinical trial

Read More

Glenmark responds to DCGI letter seeking clarification on Fabiflu

Glenmark responds to DCGI letter seeking clarification on Fabiflu

Read More